🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — June 27, 2026

Over a single day, TriWest Healthcare Alliance Corp. secured two massive firm-fixed-price delivery orders from the Department of Veterans Affairs totaling $1.78 billion, representing the entire stream's obligation. Both contracts are civilian (non-defense) and carry neutral signals, as the extremely short one-month performance periods (April and May 2026) and zero outlayed funds suggest these are urgent or bridging arrangements rather than sustainable recurring revenue. The dominant theme is a surge in VA health insurance spending, but the lack of options and short duration introduce execution and budget risk. The highest-conviction signal is the concentration risk to TriWest, which now faces a $1.78 billion revenue cliff if no follow-on awards materialize. Key watch items include outlayed fund tracking and any VA announcements regarding program continuity.

2 total filings
· daily

General Federal Contracts — June 27, 2026

Two contracts totaling $1.78 billion were awarded to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs on June 25, 2026, both for direct health and medical insurance carrier services. Both are firm-fixed-price delivery orders with extremely short one-month performance periods (April and May 2026), and neither is defense-related, reflecting a pure civilian healthcare administration theme. The highest-conviction signal is neutral: the awards are large in absolute terms but appear to be bridge or urgent-need contracts rather than recurring revenue streams, with zero outlayed funds to date on the $873.9 million award. Key risk is the lack of long-term visibility and potential budget constraints driving short-duration awards, which could signal instability in VA health insurance program funding.

2 total filings
· daily

Biotech Small-Cap Approvals — June 26, 2026

The June 26, 2026, biotech small-cap approval stream delivered six generic drug approvals (classified as 'Other'), with zero NMEs, biosimilars, or label expansions. All six approvals are neutral signals, reflecting low commercial materiality and no therapeutic area clustering. The most notable sponsor is MACLEODS PHARMS LTD, which received two approvals (RIFAPENTINE and BUPROPION HYDROCHLORIDE), indicating a modest pipeline execution capability in generics. TEVA PHARMS INC's approval of ETHINYL ESTRADIOL underscores its continued generic portfolio expansion. The absence of NMEs or breakthrough therapies limits differentiated investment insights; the key risk is the lack of high-value catalysts in this period.

6 total filings
· daily

Big Pharma Approvals — June 26, 2026

This period delivered 4 label expansion approvals, all classified as 'Other' with no NMEs or biosimilars, indicating a maintenance-oriented approval cycle. The dominant therapeutic area is oncology, with Merck's KEYTRUDA (pembrolizumab) and Pfizer's IBRANCE (palbociclib) each receiving two approvals on the same date—signal both sponsors are extending their leading franchises into additional indications. The highest-conviction signal is the dual expansion for KEYTRUDA, reinforcing Merck's position as the undisputed immuno-oncology leader and extending its peak revenue runway beyond the LOE cliff. A key watch item is that both drugs are blockbusters facing eventual IRA Medicare negotiation (small molecule IBRANCE at year 9, biologic KEYTRUDA at year 13), so each label expansion directly adds 'negotiation-proof' revenue years.

4 total filings
· daily

Orphan Drug Approvals — June 26, 2026

The June 26, 2026 orphan drug approval period featured zero NMEs, zero biosimilars, and zero label expansions, with both approvals classified as 'Other' (likely administrative or device-related label updates). The dominant therapeutic area theme is absent, as OLEZARSEN SODIUM (IONIS PHARMS INC) and PEMBROLIZUMAB (MERCK SHARP DOHME) target distinct indications. The highest-conviction signal is the label expansion for KEYTRUDA (pembrolizumab), reinforcing Merck's dominant oncology franchise, though the lack of disclosure on indication size or sales estimates limits conviction. Key risk: both approvals are low-materiality events with no disclosed commercial data, offering limited actionable intelligence for investors.

2 total filings
· daily

New Drug Approvals (Original) — June 26, 2026

The June 26, 2026 FDA approval stream is entirely composed of six FALLBACK-type biosimilar/AB-rated generic approvals, with zero NMEs, zero novel label expansions, and zero biosimilars under the traditional 351(k) pathway. The period lacks any FDA Breakthrough, Priority Review, Orphan Drug, or Accelerated Approval designations, resulting in six neutral signals and no immediate bullish or bearish catalysts for the traded universe. The dominant theme is generic drug entry into established small-molecule markets, with Macleods Pharma Ltd securing approvals for RIFAPENTINE and BUPROPION HYDROCHLORIDE, while Micro Labs, Rubicon Research, Actavis Elizabeth, and Teva Pharmaceuticals each received one approval. No significant therapeutic area clustering or sponsor pipeline strength signal is evident. The key watch item is the complete absence of NMEs, suggesting a low-catalyst day for large-cap pharma and growth-stage biotech investors, with the most relevant exposure being Teva's continued generic manufacturing capability via ETHINYL ESTRADIOL approval.

6 total filings
· daily

Federal Construction & Infrastructure Contracts — June 26, 2026

A single $341.5 million GSA contract to Gilbane-Grunley JV for the Herbert C. Hoover Building modernization formed the entirety of this period's federal construction digest, but it is entirely historical—the contract ended in September 2022 with only $862,554 in outlays remaining. The civilian-only, non-defense nature of this award underscores a lack of current procurement activity, and the neutral signal strength (3/10) combined with zero active revenue visibility offers no actionable forward trigger for investors. A key watch item is that no new GSA construction task orders or re-competes for Hoover Building phases were detected, limiting near-term growth signals for federal construction contractors.

1 total filings
· daily

DHS Homeland Security Contracts — June 26, 2026

This digest covers $162.8 million in total obligations from two DHS Homeland Security contracts awarded to Smiths Detection Inc. and Vertex Aerospace LLC, both non-defense, civilian agency awards. The dominant theme is Transportation Security Administration (TSA) investment in advanced checkpoint screening and deployment logistics, with Smiths Detection’s $83.1 million initial obligation on a $702.5 million ceiling contract providing the highest-conviction bullish signal for long-term revenue visibility through 2034. However, both contracts are firm-fixed-price, introducing execution risk on cost control, and Vertex Aerospace’s $79.7 million award has a looming 2027 end date that creates re-compete uncertainty. Key risk: Smiths Detection’s foreign ownership may face trade policy headwinds, while Vertex Aerospace’s remaining $32.2 million in un-obligated funds could be vulnerable to budget shifts.

2 total filings
· daily

VA Healthcare & Services Contracts — June 26, 2026

The two VA contracts analyzed, totaling $206.1 million, underscore a sustained federal investment in healthcare IT modernization and cybersecurity, with zero defense-related exposure. The dominant theme is the Department of Veterans Affairs' continued commitment to its Electronic Health Record Modernization (EHRM) program, led by Oracle Health Government Services ($139.4M), and a competitive win for By Light Professional IT Services LLC ($66.6M) in identity and access management. The highest-conviction signal is the sole-source nature of the Oracle award, which provides revenue certainty but limits market expansion. A key risk is the potential for budget constraints under a Continuing Resolution (CR) to delay or reduce scope on these non-defense, multi-year IT contracts.

2 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 26, 2026

This digest covers a single, low-materiality contract from the Department of Health and Human Services (HHS) to Lockheed Martin Corporation valued at $7.4 million, representing a purely civilian engagement with no defense exposure. The contract is a non-competed, labor-hours award for occupational and clinical health services in Bethesda, MD, with a short performance window ending September 2014. The highest-conviction signal is neutral, reflecting the contract's immaterial size relative to Lockheed Martin's scale and the risk of margin dilution from a 60% subcontractor reliance. Key watch items include the lack of follow-on awards and the potential for cost overruns under the labor-hours pricing structure.

1 total filings
· daily

New Federal Contractors — June 26, 2026

The 9 contracts analyzed, totaling $1.09 billion, are entirely civilian, with no defense-related awards, signaling a strong focus on non-DOD federal spending. The dominant themes are homeland security modernization (TSA screening systems) and civilian IT services (VA EHRM, Treasury analytics, OCC platform management). The highest-conviction signal is Smiths Detection Inc.'s $702.5 million TSA CT screening contract, offering long-term revenue visibility through 2034. A key risk is the low outlay percentages on large awards like Verizon Federal Inc.'s $250.8 million HHS telecom contract (only 6.6% outlaid), which may indicate execution or budget constraints.

9 total filings
· daily

Significant Contract Modifications ($10M+) — June 26, 2026

This digest of 9 significant contract modifications ($10M+) from June 26, 2026, totaling $1.09 billion, reveals a purely civilian federal procurement landscape with zero defense-related awards. The dominant theme is sustained investment in homeland security and civilian IT modernization, led by the Transportation Security Administration (TSA) and the Department of Veterans Affairs (VA). The highest-conviction signal is a bullish $83.1 million TSA award to Smiths Detection Inc. for advanced CT screening systems, offering long-term revenue visibility through 2034. A key risk is the high concentration of awards to a few agencies—TSA and VA account for over 50% of total obligation—exposing investors to potential budget reallocations or program delays.

9 total filings
· daily

Contract Deobligations Alert — June 26, 2026

The digest covers nine government contracts totaling $1.09 billion, all from civilian agencies (0% defense-related), signaling a heavy focus on non-defense federal spending. The dominant themes are homeland security screening technology (Smiths Detection, Vertex Aerospace) and health IT modernization (Oracle Health, VA). The highest-conviction signal is a bullish $83.1 million TSA award to Smiths Detection with a $702.5 million ceiling through 2034, indicating strong revenue visibility. A key risk is the low outlay percentage on large contracts like Verizon Federal's $250.8 million HHS award (only 6.6% outlaid), suggesting potential execution or budget issues. Overall, the digest points to sustained civilian IT and security spending but with execution risks on older, under-utilized contracts.

9 total filings
· daily

Contract Option Exercises — June 26, 2026

The digest covers 9 contract option exercises totaling $1.09 billion, all from civilian agencies (0% defense-related), with an average signal strength of 5.2/10. The dominant theme is civilian IT modernization and security infrastructure, led by the Department of Homeland Security (TSA) and the Department of Veterans Affairs. The highest-conviction signal is Smiths Detection Inc.'s $702.5 million TSA CT screening contract (initial $83.1 million obligation), offering long-term revenue visibility through 2034. A key risk is the low outlay rate on Verizon Federal Inc.'s $250.8 million HHS telecom contract (only 6.6% outlaid), which may indicate execution or budget issues. Overall, the digest suggests stable but modest civilian agency spending, with no defense exposure and limited near-term growth catalysts.

9 total filings
· daily

Federal Professional Services Contracts — June 26, 2026

This digest covers a single $79.7 million civilian contract awarded to VERTEX AEROSPACE LLC by the Transportation Security Administration (DHS) for screening equipment deployment services. The contract is entirely civilian, with no defense-related awards, and the average signal strength is neutral at 6.0/10. The highest-conviction signal is the stable, multi-year revenue stream through February 2027, but the fixed-price structure introduces execution risk. Key watch items include the remaining $32.2 million in unfunded obligations and the approaching 2027 re-compete.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — June 26, 2026

In a single-day digest covering four civilian-sector federal IT contracts totaling $327.9 million, the Department of Veterans Affairs dominated with 63% of aggregate obligations ($206.1M), driven by Oracle Health's $139.4M sole-source EHRM task order and By Light's $66.6M identity management delivery order. The only bullish signal—Procentrix's $60.2M Treasury/OCC platform support contract—reflects strong execution (92% of value outlayed) and competitive viability. Key risks include Oracle Health's performance-dependent fixed-price structure and potential budgetary constraints on VA EHRM expansion. No defense-related awards were noted, underscoring a pure civilian IT modernization theme.

4 total filings
· daily

All HHS Contracts — June 26, 2026

The two HHS contracts analyzed total $258.1 million, with no defense-related awards. The dominant theme is a single massive, long-term telecom contract awarded to Verizon Federal Inc. worth $250.8 million, but only 6.6% has been outlaid, raising questions about execution and revenue recognition. A small, sole-source health services contract to Lockheed Martin ($7.4M) highlights a trusted relationship but heavy subcontractor reliance. The highest-conviction signal is the Verizon contract's low outlay, which may indicate budget constraints or shifting priorities within HHS. Key risk includes monitoring Verizon's contract execution and potential re-compete after the 2023 end date.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 26, 2026

The three mega contracts totaling $731.6 million are entirely civilian, with zero defense exposure, signaling a quiet period for defense prime contractors. The largest award, a $341.5 million GSA construction contract to Gilbane-Grunley JV, is largely completed and offers no forward revenue. The highest-conviction signal is the $139.4 million VA EHRM task order to Oracle Health Government Services, which indicates sustained federal health IT investment but carries execution risk due to its sole-source nature. A key risk is the low outlay on Verizon Federal's $250.8 million HHS telecom contract, suggesting potential underperformance or budget constraints.

3 total filings
· daily

High-Value Federal Grants ($5M+) — June 26, 2026

This digest covers 9 high-value federal grants totaling $1.09 billion, all awarded by civilian agencies with zero defense-related contracts, underscoring a non-DoD procurement focus. The dominant sector theme is civilian IT modernization and security, led by the Department of Homeland Security (TSA) and the Department of Veterans Affairs, with the highest-conviction signal being Smiths Detection Inc.'s $702.5 million ceiling contract for CT checkpoint screening systems, offering long-term revenue visibility through 2034. A key risk is the low outlay percentage on several large contracts—notably Verizon Federal Inc.'s $250.8 million HHS telecom award with only 6.6% outlayed—raising questions about actual execution and revenue recognition. Investors should monitor TSA budget allocations and VA EHRM program milestones as critical watch items.

9 total filings
· daily

General Federal Contracts — June 26, 2026

This digest covers $1.09 billion in aggregate obligations across 9 contracts, all civilian (0/9 defense-related), with an average signal strength of 5.2/10. The dominant theme is civilian agency IT modernization and security infrastructure, led by the Department of Homeland Security (TSA) and Department of Veterans Affairs, which together account for $303.4 million in obligations. The highest-conviction signal is Smiths Detection Inc.'s $702.5 million ceiling contract for CT checkpoint screening systems, offering long-term revenue visibility through 2034. A key risk is the concentration of large, aged contracts (Gilbane-Grunley JV's $341.5M GSA contract and Verizon Federal's $250.8M HHS contract) that are largely completed or under-executed, inflating the aggregate total without providing forward revenue. Investors should focus on the active, high-visibility awards to Smiths Detection, Oracle Health, and By Light Professional IT Services for near-term civilian sector exposure.

9 total filings